These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 22464245)

  • 1. 3.0 T multiparametric prostate MRI using pelvic phased-array coil: utility for tumor detection prior to biopsy.
    Rosenkrantz AB; Mussi TC; Borofsky MS; Scionti SS; Grasso M; Taneja SS
    Urol Oncol; 2013 Nov; 31(8):1430-5. PubMed ID: 22464245
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prostate cancer in magnetic resonance imaging: diagnostic utilities of spectroscopic sequences.
    Caivano R; Cirillo P; Balestra A; Lotumolo A; Fortunato G; Macarini L; Zandolino A; Vita G; Cammarota A
    J Med Imaging Radiat Oncol; 2012 Dec; 56(6):606-16. PubMed ID: 23210579
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multiparametric magnetic resonance imaging of the prostate can improve the predictive value of the urinary prostate cancer antigen 3 test in patients with elevated prostate-specific antigen levels and a previous negative biopsy.
    Sciarra A; Panebianco V; Cattarino S; Busetto GM; De Berardinis E; Ciccariello M; Gentile V; Salciccia S
    BJU Int; 2012 Dec; 110(11):1661-5. PubMed ID: 22564540
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prostate cancer detection in patients with total serum prostate-specific antigen levels of 4-10 ng/mL: diagnostic efficacy of diffusion-weighted imaging, dynamic contrast-enhanced MRI, and T2-weighted imaging.
    Tamada T; Sone T; Higashi H; Jo Y; Yamamoto A; Kanki A; Ito K
    AJR Am J Roentgenol; 2011 Sep; 197(3):664-70. PubMed ID: 21862809
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dynamic contrast-enhanced MRI of prostate cancer at 3 T: a study of pharmacokinetic parameters.
    Ocak I; Bernardo M; Metzger G; Barrett T; Pinto P; Albert PS; Choyke PL
    AJR Am J Roentgenol; 2007 Oct; 189(4):849. PubMed ID: 17885055
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of Diffusion Kurtosis Imaging Versus Standard Diffusion Imaging for Detection and Grading of Peripheral Zone Prostate Cancer.
    Roethke MC; Kuder TA; Kuru TH; Fenchel M; Hadaschik BA; Laun FB; Schlemmer HP; Stieltjes B
    Invest Radiol; 2015 Aug; 50(8):483-9. PubMed ID: 25867657
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Usefulness of comparing of magnetic resonance imaging (MRI) findings prior to repeat biopsy and negative initial biopsy as a decision-making method for repeat prostate biopsy].
    Sawazaki H; Sengiku A; Imamura M; Takahashi T; Ogura K; Kobayashi H
    Hinyokika Kiyo; 2014 Apr; 60(4):165-70. PubMed ID: 24882227
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The accuracy of multiparametric MRI in men with negative biopsy and elevated PSA level--can it rule out clinically significant prostate cancer?
    Abd-Alazeez M; Ahmed HU; Arya M; Charman SC; Anastasiadis E; Freeman A; Emberton M; Kirkham A
    Urol Oncol; 2014 Jan; 32(1):45.e17-22. PubMed ID: 24055430
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Usefulness of diffusion-weighted imaging and dynamic contrast-enhanced magnetic resonance imaging in the diagnosis of prostate transition-zone cancer.
    Yoshizako T; Wada A; Hayashi T; Uchida K; Sumura M; Uchida N; Kitagaki H; Igawa M
    Acta Radiol; 2008 Dec; 49(10):1207-13. PubMed ID: 19031184
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined magnetic resonance spectroscopy and dynamic contrast-enhanced imaging for prostate cancer detection.
    Perdonà S; Di Lorenzo G; Autorino R; Buonerba C; De Sio M; Setola SV; Fusco R; Ronza FM; Caraglia M; Ferro M; Petrillo A
    Urol Oncol; 2013 Aug; 31(6):761-5. PubMed ID: 21906966
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [MRI staging of prostate cancer with the combined endorectal body phased-array coil and histologic correlation].
    Pegios W; Bentas W; Wittmann L; Mack MG; Zangos S; Söllner O; Binder J; Fellbaum C; Jonas D; Vogl TJ
    Rofo; 2003 Dec; 175(12):1660-6. PubMed ID: 14661137
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patients with a history of elevated prostate-specific antigen levels and negative transrectal US-guided quadrant or sextant biopsy results: value of MR imaging.
    Beyersdorff D; Taupitz M; Winkelmann B; Fischer T; Lenk S; Loening SA; Hamm B
    Radiology; 2002 Sep; 224(3):701-6. PubMed ID: 12202702
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A role of multifactorial evaluation of prostatic 3T MRI in patients with elevated prostatic-specific antigen levels: prospective comparison with ultrasound-guided transrectal biopsy.
    Ferda J; Kastner J; Hora M; Hes O; Fínek J; Topolčan O; Kreuzberg B
    Anticancer Res; 2013 Jun; 33(6):2791-5. PubMed ID: 23749943
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prostate cancer: role of pretreatment multiparametric 3-T MRI in predicting biochemical recurrence after radical prostatectomy.
    Park JJ; Kim CK; Park SY; Park BK; Lee HM; Cho SW
    AJR Am J Roentgenol; 2014 May; 202(5):W459-65. PubMed ID: 24758681
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Negative predictive value for cancer in patients with "gray-zone" PSA level and prior negative biopsy: preliminary results with multiparametric 3.0 Tesla MR.
    Girometti R; Bazzocchi M; Como G; Brondani G; Del Pin M; Frea B; Martinez G; Zuiani C
    J Magn Reson Imaging; 2012 Oct; 36(4):943-50. PubMed ID: 22649035
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prebiopsy multiparametric 3T prostate MRI in patients with elevated PSA, normal digital rectal examination, and no previous biopsy.
    Jambor I; Kähkönen E; Taimen P; Merisaari H; Saunavaara J; Alanen K; Obsitnik B; Minn H; Lehotska V; Aronen HJ
    J Magn Reson Imaging; 2015 May; 41(5):1394-404. PubMed ID: 24956412
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Usefulness of pre-biopsy multiparametric magnetic resonance imaging and clinical variables to reduce initial prostate biopsy in men with suspected clinically localized prostate cancer.
    Numao N; Yoshida S; Komai Y; Ishii C; Kagawa M; Kijima T; Yokoyama M; Ishioka J; Matsuoka Y; Koga F; Saito K; Masuda H; Fujii Y; Kawakami S; Kihara K
    J Urol; 2013 Aug; 190(2):502-8. PubMed ID: 23473904
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multiparametric magnetic resonance imaging guided diagnostic biopsy detects significant prostate cancer and could reduce unnecessary biopsies and over detection: a prospective study.
    Thompson JE; Moses D; Shnier R; Brenner P; Delprado W; Ponsky L; Pulbrook M; Böhm M; Haynes AM; Hayen A; Stricker PD
    J Urol; 2014 Jul; 192(1):67-74. PubMed ID: 24518762
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thirty-two-channel coil 3T magnetic resonance-guided biopsies of prostate tumor suspicious regions identified on multimodality 3T magnetic resonance imaging: technique and feasibility.
    Hambrock T; Fütterer JJ; Huisman HJ; Hulsbergen-vandeKaa C; van Basten JP; van Oort I; Witjes JA; Barentsz JO
    Invest Radiol; 2008 Oct; 43(10):686-94. PubMed ID: 18791410
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Value of endorectal MRI and MRS in patients with elevated prostate-specific antigen levels and previous negative biopsies to localize peripheral zone tumours.
    Cirillo S; Petracchini M; Della Monica P; Gallo T; Tartaglia V; Vestita E; Ferrando U; Regge D
    Clin Radiol; 2008 Aug; 63(8):871-9. PubMed ID: 18625351
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.